Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta

No Definitive Decision Yet On Avenue Deal

Executive Summary

Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.

You may also be interested in...



Lupin Delivers On Generic Fostair With UK Luforbec Launch

Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential significant cost savings” for the UK’s National Health Service.

FDA Looks To Solve Chantix Shortage With Par ANDA Approval

Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.

After Lupin Launch, Cipla Introduces US Brovana Rival

After Lupin’s launch of an authorized generic, Cipla has entered the US market with its own generic rival to Sunovion’s Brovana, after receiving the FDA approval for the inhalation solution. Axar Pharma and Glenmark also currently hold approvals and Teva a tentative approval for arformoterol tartrate abbreviated new drug applications.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel